News
12-13-2009, 10:21 PM
ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710).
More... (http://www.news-medical.net/news/20091214/ImmunoGen-announces-the-presentation-of-positive-trastuzumab-DM1-clinical-data.aspx)
More... (http://www.news-medical.net/news/20091214/ImmunoGen-announces-the-presentation-of-positive-trastuzumab-DM1-clinical-data.aspx)